Erb-b2 receptor tyrosine kinase 2
Synonyms: CD340, HER-2, HER2, NGL, “human epidermal growth factor receptor 2”, NEU, “neuro/glioblastoma derived oncogene homolog”
ERBB2 is a receptor tyrosine kinase that is part of the epidermal growth factor (EGF) family1. It undergoes dimerization with other EGF receptors, with HER2/HER3 dimer being the most active and tumor promoting combination2. Aberrant signaling from HER2/HER3 heterodimers leads to deregulated PI3K signaling, which may predict for poor clinical outcome and resistance to various cancer therapies3.
ERBB2 kinase assay is run on mobility shift microfluidics platform (Caliper), which provides best in industry quality of data. We routinely run services associated with this kinase including: screening, profiling, dose-response studies and kinetic measurements. Please contact us for more information.
1. Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemotherapy research and practice. 2012 Dec 20;2012.
2. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene. 1995 May 4;10(9):1813-22.
3. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2–positive breast cancer. Journal of Clinical Oncology. 2009 Nov 2;27(34):5838-47.